HUMORAL IMMUNE-RESPONSE TO A YEAST-DERIVED HEPATITIS-B VACCINE IN PATIENTS WITH TYPE-1 DIABETES-MELLITUS

被引：26

作者：

BOUTER, KP ^{[1
]}

DIEPERSLOOT, RJA ^{[1
]}

WISMANS, PJ ^{[1
]}

MEYLING, FHIG ^{[1
]}

HOEKSTRA, JBL ^{[1
]}

HEIJTINK, RA ^{[1
]}

VANHATTUM, J ^{[1
]}

机构：

[1] DIAKONESSEN HOSP,DEPT INTERNAL MED,UTRECHT,NETHERLANDS

来源：

DIABETIC MEDICINE | 1992年 / 9卷 / 01期

关键词：

HEPATITIS-B VACCINE; IMMUNE RESPONSE; TYPE-1; DIABETES;

D O I：

10.1111/j.1464-5491.1992.tb01717.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The immune response following vaccination with a recombinant hepatitis B vaccine was investigated in 32 patients with Type 1 diabetes mellitus and compared with the outcome in 32 healthy age- and sex-matched volunteers. Participants were vaccinated at 0, 30, and 180 days and in vivo immune response was determined at 30, 60, 90, 180, and 210 days. The number of responders (anti-HBs > 1 IU l-1) was significantly lower (p < 0.05) among patients at 30 (2 vs 11), 60 (17 vs 26), 90 (20 vs 28) and 180 (22 vs 29) days. The number of patients protected (anti-HBs > 10 IU l-1) was lower (p < 0.05) than the number of protected volunteers at 60 (5 vs 14), 90 (10 vs 19), 180 (15 vs 24), and 210 days (24 vs 31). After the complete course of vaccination 8 out of 32 patients were still unprotected against hepatitis B (p < 0.05). The anti-HBs titre of responders at 210 days was 251 (20, 3162) (geometric mean (-SD, + SD)) IU l-1 in patients and 1259 (126, 12589) IU l-1 in control subjects (p < 0.05). The HLA-antigen DQw1 frequency in the diabetic low responders (anti-HBs < 100 IU l-1) was 0.27 compared with 0.86 in diabetic adequate responders. No relation between anti-HBs production and concentration of HbA1c could be demonstrated.

引用

页码：66 / 69

页数：4

共 30 条

[1]

Belshe RB., Textbook of Human Virology, pp. 735-736, (1984)

[2]

Dudley FJ, Scheuer PJ, Sherlock S., Natural history of hepatitis‐associated antigen‐positive chronic liver disease, Lancet, 2, pp. 1388-1393, (1972)

[3]

Beasley RP, Lin C-C, Hwang L-Y., Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan, Lancet, 2, pp. 1129-1131, (1981)

[4]

Madalinski K., Brzosko WJ, Malczewski M., Czyzyk A., Australia antigen in sera of diabetic patients, Lancet, 1, pp. 701-702, (1972)

[5]

Meluzin F., Kubecova F., Spicka J., Australia antigen in medical personnel and diabetic patients, Cas Lek Cesk, 113, pp. 1387-1389, (1974)

[6]

Khalil KG, Munir H., Shamma A., Abourizk N., Hepatitis B virus markers in diabetes mellitus, Diabetes Care, 8, pp. 250-253, (1985)

[7]

Pozzilli P., Arduini P., Visalli N., Sutherland J., Pezzella M., Galli C., Et al., Reduced protection against hepatitis B virus following vaccination in patients with type I (insulin dependent) diabetes, Diabetologia, 30, pp. 817-819, (1987)

[8]

Van Rood JJ., Microlymphocytotoxicity method, Manual of Tissue Typing Techniques, pp. 104-105, (1979)

[9]

Van Leeuwen A., Van Rood JJ., Description of B‐cell methods, Histocompatibility Testing 1980, pp. 278-279, (1980)

[10]

Schuurman HJ, Van Baarlen J., Huppes W., Lam BW, Verdonck LF, Van Unnik JAM., Immunophenotyping of Non‐Hodgkins Lymphoma. Lack of correlation between immunophenotype and cell morphology, Am J Path, 129, pp. 140-151, (1987)

← 1 2 3 →